This study evaluated the feasibility of mid-trimester U/S PCI localization to correctly predict PCI at delivery. STUDY DESIGN: Prospective observational trial including patients with singleton gestation between 18-22 weeks presenting for fetal anatomical screening U/S at a single institution between 1/1/2013-12/31/2013. PCI was assessed using gray scale and color doppler and categorized as central/eccentric, marginal (<2 cm was placental edge) or velamentous. The study group was comprised of those patients who delivered at the study site, in whom placenta was examined and PCI similarly categorized following delivery. The accuracy of mid-trimester U/S to predict PCI at delivery was determined by comparing antenatal prediction with actual PCI after delivery. The screening efficacy of mid-trimester U/S to predict abnormal PCI (marginal or velamentous) at term was determined. RESULTS: PCI was localized and documented in 919/942 (97.5%) at time of the mid-trimester screening ultrasound, PCI(U).The study group included 596 (64.9%) patients who delivered at the study site, in whom PCI was documented after delivery, PCI(D). Abnormal PCI was identified in 23/596 (3.9%) of placentas after delivery-5 (0.8%) velamentous and 18 (3.0%) marginal insertions. The sensitivity, specificity, negative predictive value, positive predictive value of midtrimester U/S in predicting abnormal PCI at delivery was 21.7%, 96.0%, 96.8%, and 17.9%, respectively.
CONCLUSION:
Although readily imaged at time of mid-trimester U/S, the ability to accurately predict abnormal PCI at delivery is poor. Any proposed antenatal management strategy for PCI abnormalities diagnosed by U/S requires consideration of the prenatal diagnostic limitations.
Prenatal diagnosis of congenital face and neck malformations -is complementary fetal MRI of value?
Roni Zemet 1,2 , Inna Amdur-Zilberfarb 2 , Moran Shapira 1,2 , Tomer Ziv-Baran OBJECTIVE: Fetal face and neck anomalies represent a challenging prenatal diagnosis, mainly because of the wide range of morphological features involved. The aim of this study was to evaluate the role of fetal magnetic resonance imaging (MRI) as a complement to ultrasound (US) in the prenatal diagnosis of face and neck anomalies. STUDY DESIGN: This was a historical cohort study including all pregnant women who were referred for fetal MRI due to antenatal diagnosis of face or neck anomalies on screening US between 2011 and 2016 in a single tertiary referral center. A comparison group was composed of pregnant women who were referred for fetal MRI due to indications other than face or neck malformations. Demographic and clinical data were collected from the electronic records and through direct phone interviews. Prenatal US findings, MRI findings, and postnatal diagnosis were compared for consistencies and discrepancies. RESULTS: Forty-five pregnant women with 73 suspected fetal face or neck anomalies diagnosed by screening US underwent MRI at a mean gestational age of 31.7. The comparison group comprised 61 women. In 40 out of 73 anomalies (54.8%), US and MRI findings were in complete agreement with postnatal diagnoses. MRI correctly ruled out the diagnosis of 24 anomalies suspected on US. MRI diagnosed four additional pathologies that were not demonstrated by US, with three of which being a cleft palate. Three anomalies interpreted correctly by US were not diagnosed on MRI. In six cases, the diagnosis by both US and MRI were incorrect when correlated with the postnatal outcome. Seven anomalies detected on postnatal examination were not recognized by both US and MRI. There was over-diagnosis of one anomaly in fetal MRI compared to postnatal examination. Out of the 85 anomalies (suspected or confirmed), confident diagnosis could be made by MRI in 68 anomalies (80%), not diagnosed in 10 (11.8%), and over-diagnosed in 7 (8.2%). By US, confident diagnosis could be made in 44 anomalies (51.8%), not diagnosed in 11 (12.9%), and over-diagnosed in 30 (35.3%). Using postnatal diagnosis as a standard of reference, a comparably high sensitivity and specificity for the detection of specific face or neck anomalies were found for both US and MRI (table) . CONCLUSION: In our study, MRI found to have higher diagnostic accuracy in the evaluation of fetal face and neck anomalies relative to US. Therefore, MRI is a useful adjunct to US in the prenatal work-up of face and neck anomalies.
1055 Treatment of amniotic fluid sludge is not associated with decreased incidence of preterm birth OBJECTIVE: To evaluate the incidence of preterm birth (PTB) amongst patients with amniotic fluid sludge according to whether or not they had been treated with antibiotics following initial diagnosis. Additional maternal and neonatal outcomes were evaluated according to cohort. STUDY DESIGN: We performed a retrospective cohort study of all patients diagnosed with amniotic fluid sludge in the outpatient ultrasound suite at a single academic center between 2010-2017. Patients were separated into cohorts based on whether or not they had been treated with antibiotics at the time of diagnosis. Patients with multiple gestation, fetal anomalies, pre-viable preterm rupture of membranes prior to initial diagnosis of amniotic fluid sludge, active preterm labor, placenta previa and/or suspected accreta were excluded. Primary outcome of preterm birth was compared by univariate analysis as well as regression analysis, so as to control for potential co-linear and/or confounding variables. Additional outcomes were compared by univariate analysis. RESULTS: A total of 181 patients were identified and considered for inclusion. 97 met inclusion criteria. Of those, 51 were treated with PO antibiotics (46 with PO azithromycin and 5 with PO moxifloxacin) and 46 were not treated. The incidence of PTB < 37 wks was 49.4 % (48/97) and PTB < 28 wks was 22.7% (22/97). There was no significant difference in incidence of preterm birth between the two cohorts, either < 37 weeks (p¼0.47) or < 28 weeks (p¼0.83). After adjusting for race, BMI, tobacco use, cervical length and PTB history, the incidence of PTB with antibiotic treatment remained insignificant (OR 1.3, 0.77-1.9). No differences were seen in the incidence of PPROM (p¼0.94) or mean latency from diagnosis (p¼0.95). Neonatal outcomes including birthweight (p¼0.77), sepsis (p¼0.53), IVH (p¼0.95), LOS (p¼0.46), and NICU admission (p¼0.08) were not different between cohorts. There was no difference in the incidence of either clinical or pathologic chorioamnionitis between cohorts (p¼0.92 and 0.14, respectively). CONCLUSION: Antibiotic treatment administered after the initial diagnosis of amniotic fluid sludge is not associated with a reduction in the rates of premature birth when compared to expectant management. Likewise, treatment of amniotic fluid sludge was not associated with improvement in evaluated obstetric, pathologic, or neonatal variables compared to expectant management. These findings demonstrate the need for a prospective trial.
1056 Placental corticotrophin-releasing hormone (pCRH) as a possible modulator of human fetal liver blood perfusion Charité University Medicine, Berlin, Berlin OBJECTIVE: Fetal liver blood flow (fLBF) has recently emerged as a process of interest in terms of its putative role in influencing fetal growth and subsequent newborn and infant body composition (fat mass percentage). However, the determinants of variation in fLBF are poorly understood. Placental corticotrophin-releasing hormone (pCRH) has been implicated as a key endocrine mediator of placental-fetal perfusion, birth outcomes, and subsequent infant developmental and health outcomes.The objective of the present study was to determine whether circulating levels of pCRH across gestation are associated with fLBF. STUDY DESIGN: A prospective study was conducted in a cohort of 79 uncomplicated singleton pregnancies. Fetal ultrasonography was performed at 30 weeks gestation for conventional fetal biometry and characterization of fLBF (quantified by subtracting ductus venosus flow from umbilical vein flow). pCRH was quantified in maternal circulation at approximately 12, 20 and 30 weeks gestation. Multiple regression analysis was used to determine the proportion of variation in fLBF explained by pCRH. Co-variates included maternal age, parity, pre-pregnancy body mass index, gestational weight gain, gestational age at birth, and infant sex. RESULTS: fLBF at 30 weeks was 68.4 AE 4.1 ml/min. pCRH concentrations in early, mid and later gestation were 12.5 AE 0.91 pg/ml (mean AE SEM), 35.7 AE 2.77 pg/ml, and 247.9 AE 18.88 pg/ml, respectively. pCRH assessed at 12 weeks and 20 weeks was not associated with fLBF. pCRH at 30 weeks was significantly and positively associated with fLBF (r ¼ 0.319, p ¼ 0.004). After accounting for the effects of covariates, pCRH at 30 weeks gestation explained 11.6% of the variance in fLBF. CONCLUSION: Placental CRH is a possible modulator of fLBF, and may constitute a biochemical marker for clinical investigational and
